Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Hypomethylating agent with venetoclax versus hypomethylating agent alone in frontline management of myelodysplastic syndrome - impact of subgroups on clinical outcomes

View Full Paper
Ask AI
Bookmark
Share

Authors

YAYasmin AbazaSBSomedeb BallMHMichael Haddadin

Discussion

Loading...

Member takes

Overview

Multicenter study demonstrates that venetoclax combined with hypomethylating agent enhances survival in specific myelodysplastic syndrome patients, suggesting potential tailored therapies.

Key Points

  • To evaluate the effectiveness of hypomethylating agent combined with venetoclax on clinical outcomes in myelodysplastic syndrome patients.
  • Multicenter retrospective analysis from 19 US academic centers
  • Included adults with intermediate to very high-risk myelodysplastic syndrome
  • Compared outcomes of patients receiving HMA-VEN versus HMA monotherapy
  • Used Kaplan-Meier method for survival analysis
  • Employed multivariable regression models to identify determinants of outcomes.
  • Significantly improved overall survival in patients treated with HMA-VEN versus HMA monotherapy
  • Median overall survival was 22.4 months for HMA-VEN compared to 18.1 months for HMA
  • Response rate was higher in HMA-VEN group: 81% vs 39% for HMA
  • TP53 mutation status was a significant predictor for overall survival
  • Benefits of HMA-VEN were noted in specific patient subgroups.

Cite This Study

Abaza et al. (2025) studied this question.

synapsesocial.com/papers/69362f5d4fa91c937236dc64https://doi.org/10.1182/blood-2025-239
View Full Paper
Ask AI
Bookmark
Share